

**Tiglutik™ (riluzole) Oral Suspension**  
**Exservan™ (riluzole) oral film**  
**Effective 01/01/2023**

<b>Plan</b>	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	<b>Program Type</b>	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
<b>Benefit</b>	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit		
<b>Specialty Limitations</b>	N/A		
<b>Contact Information</b>	<b>Medical and Specialty Medications</b>		
	All Plans	Phone: 877-519-1908	Fax: 855-540-3693
	<b>Non-Specialty Medications</b>		
	All Plans	Phone: 800-711-4555	Fax: 844-403-1029
<b>Exceptions</b>	N/A		

### Overview

Tiglutik and Exservan are indicated for the treatment of amyotrophic lateral sclerosis (ALS)

### Coverage Guidelines

Authorization may be reviewed for members new to the plan who are currently receiving treatment with Tiglutik or Exservan excluding when the product is obtained as samples or via manufacturer's patient assistance programs.

#### OR

Authorization may be granted for members when ALL the following criteria are met, and documentation is provided:

1. Member is diagnosed with amyotrophic lateral sclerosis (ALS)
2. Member is at least 18 years of age
3. Member has documented inability to swallow oral riluzole tablets

### Limitations

1. Initial and reauthorizations will be granted for 24 months.
2. The following quantity limits apply:

Exservan 50mg oral film	60 films per 30 days
-------------------------	----------------------

### References

1. Tiglutik (riluzole) [prescribing information]. Berwyn, PA: ITF Pharma Inc; December 2019.
2. Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2012; CD001447.
3. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994; 330:585.
4. Kennel P, Revah F, Bohme GA, et al. Riluzole prolongs survival and delays muscle strength deterioration in mice with progressive motor neuronopathy (pnm). J Neurol Sci 2000; 180:55.
5. Exservan (riluzole) [prescribing information]. Warren, NJ: Aquestive Therapeutics; July 2022.

**Review History**

02/20/19 – Reviewed

07/21/2021 – Reviewed July P&T; update document to include started and stabilized statement, added new formulation Exservan; references updated

09/21/2022 - Reviewed at Sept P&T; references updated; no clinical changes.

